Zepbound (Tirzepatide): Dosing, Cost, and What to Expect

Zepbound: A Complete Patient Guide

Zepbound (tirzepatide) is an FDA-approved prescription medication for chronic weight management. Manufactured by Eli Lilly, it was approved by the FDA on **November 8, 2023**. Zepbound is the first and only dual GIP/GLP-1 receptor agonist approved specifically for weight loss.

Who Is Eligible for Zepbound?

Per the FDA-approved labeling, Zepbound is indicated for adults with:

Like all GLP-1 weight loss medications, Zepbound must be used alongside a reduced-calorie diet and increased physical activity.

In December 2024, the FDA also approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.

How Zepbound Differs from Other GLP-1 Medications

Zepbound contains tirzepatide, which activates **two** hormone receptors:

1. **GLP-1 receptor** -- the same target as semaglutide (Wegovy/Ozempic)

2. **GIP receptor** -- glucose-dependent insulinotropic polypeptide

This dual mechanism is believed to produce greater appetite suppression and metabolic effects compared to medications that target only GLP-1. In head-to-head comparisons across trials, tirzepatide has demonstrated greater average weight loss than semaglutide alone.

Dosing Schedule

Zepbound also uses a gradual escalation schedule:

| Period | Dose |

|--------|------|

| Weeks 1-4 | 2.5 mg weekly |

| Weeks 5-8 | 5 mg weekly |

| Week 9+ | May increase to 10 mg, then 15 mg (based on response and tolerability) |

Maximum dose is 15 mg weekly. The medication is a once-weekly subcutaneous injection using a prefilled pen or single-dose vial.

Side Effects

From the SURMOUNT-1 trial data and FDA prescribing information, the most common side effects (approximate rates across doses):

Side effect rates are dose-dependent, with higher rates at the 10 mg and 15 mg doses. As with semaglutide, gastrointestinal symptoms tend to decrease over time on a stable dose. Approximately 4-7% of trial participants discontinued treatment due to side effects.

**Serious warnings:** Zepbound carries the same boxed warning as other GLP-1 medications regarding thyroid C-cell tumors in animal studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN type 2.

Cost

Zepbound's manufacturer list price is approximately **$1,086 per month**. Eli Lilly also offers Zepbound in single-dose vials at lower price points. Insurance coverage is improving but varies by plan. Eli Lilly offers a savings card program for eligible commercially insured patients.

Expected Results

Based on the SURMOUNT-1 trial (NEJM 2022):

*Zepbound requires a prescription from a licensed healthcare provider. This guide is for educational purposes and does not replace medical advice.*